To include your compound in the COVID-19 Resource Center, submit it here.

The new queue

The new queue

Company S-1update New funding goal Shares Price range Post-$ target Lead program Original goal Original filing
Aderis 10/2 $78M 6.5M $11-$13 $260.3 Ph III Up to $75M 8/27
CancerVax

Read the full 344 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE